

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

Ira Jacobs, Danielle Petersel, Lesley G. Shane, Chee-Keng Ng, Carol Kirchhoff, Gregory Finch, Sadiq Lula

Corresponding author: Ira Jacobs; Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA. Email: ira.jacobs@pfizer.com

Supplemental Table S5. Top 10 identified congresses publishing reports on biosimilars (2009–August 2015)

Congress abstract (total records, all years)	Year						
	2009	2010	2011	2012	2013	2014	2015
EULAR (48)	–	–	–	3	5	18	22
ISPOR (33)	1	–	–	3	9	13	7
AAPS National Biotech (24)	–	–	–	1	9	6	8
ACR (20)	–	–	–	1	6	13	–
ECCO (14)	–	–	–	–	–	3	11
CASSS WCBP (13)	–	–	–	–	–	8	5
CASSS Mass Spec (11)	–	–	–	–	6	5	–
SoT (11)	–	–	–	6	2	1	2
ASCO (11)	–	–	1	–	2	5	3
CASSS HOS (7)	–	–	–	–	5	1	1
Total	1	0	1	14	44	73	59

AAPS American Association of Pharmaceutical Scientists; ACR American College of Rheumatology; ASCO American Society of Clinical Oncology; CASSS California Separation Science Society; WCBP Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products; HOS Symposium on Higher Order Structure of Protein Therapeutics; ECCO European Crohn's and Colitis Organization; EULAR European League Against Rheumatism; ISPOR International Society for Pharmacoeconomics and Outcomes Research; SoT Society of Toxicology